Aerie Pharmaceuticals to Present at Two Investor Conferences in September
September 06 2017 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced that
company management will present at the following conferences in
September.
- Rodman & Renshaw 19th Annual Global
Investment Conference (sponsored by H.C. Wainwright & Co., LLC)
- Presentation Date: Tuesday, September
12, 2017
- Presentation Time: 12:30pm E.T.
- Location: New York, NY
- Cantor Fitzgerald 2017 Global
Healthcare Conference
- Presentation Date: Wednesday, September
27, 2017
- Presentation Time: 9:10am E.T.
- Location: New York, NY
The presentations will be webcast live and may be accessed by
visiting Aerie's website at http://investors.aeriepharma.com/. A
replay of each webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two current product candidates are
once-daily intraocular pressure lowering therapies with novel
mechanisms of action to treat patients with glaucoma or ocular
hypertension. The NDA (new drug application) for Rhopressa™
(netarsudil ophthalmic solution) 0.02% was submitted to
the U.S. Food and Drug Administration (FDA)
in February 2017, and, in May 2017, the FDA set
the PDUFA (Prescription Drug User Fee Act) goal date for the
completion of the FDA’s review of the Rhopressa™ NDA
for February 28, 2018. Aerie’s second product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution)
0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and
widely prescribed PGA latanoprost, achieved its primary
efficacy endpoint in two Phase 3 registration trials, named Mercury
1 and Mercury 2, and also achieved successful 12-month safety and
efficacy results in Mercury 1. The Roclatan™ NDA submission is
expected to take place in the first half of 2018. Aerie is also
focused on the development of additional product candidates and
technologies in ophthalmology.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906005155/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsAmi Bavishi,
212-213-0006abavishi@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Oct 2023 to Oct 2024